Treatment of mycosis fungoides with OK-432.
Up to the present no other therapeutic means besides local X-ray or beta-ray irradiation and anticancer drugs for the treatment of patients with mycosis fungoides, especially when the condition has progressed to secondary involvement of the lymph nodes, has been found. A recent clinical trial of OK-432 injected locally into cutaneous tumors of a patient with this disease resulted in a conspicuous contraction not only of the tumors injected but of other tumors as well along with significant regression of lymphadenomas. No serious adverse reaction was observed other than low-grade fever and heavy-headedness. These results suggest host-mediated and direct antitumor effects of OK-432 as the possible underlying mechanisms. The efficacy of OK-432 in reducing the size of the tumors without causing any serious adverse effects indicate the potential usefulness of this drug for the treatment of mycosis fungoides.
Sawada
Y
Y
Department of Dermatology, Nagoya University School of Medicine, 65 Tsurumai-cho, Showaku, Nagoya 466, Japan.
Ohashi
M
M
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001707:Biopsy, Needle; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D015552:Injections, Intralesional; D007564:Japan; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology*; D009367:Neoplasm Staging; D010844:Picibanil / Q000627:therapeutic use*; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D010844:Picibanil